(IDRW) International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 4-8, 2013; Toronto, ON, Canada

Conference Reports for NATAP


(IDRW) International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies June 4-8, 2013 Toronto, ON, Canada

	Report on International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 4-8, 2013 Toronto, Canada written by Mark A. Wainberg McGill University AIDS Centre, Montreal, Canada (06/17/13) Primary and Secondary Analyses of Emergent Drug Resistance through Week 48 from the STaR Study: Rilpivirine/Emtricitabine/Tenofovir DF vs. Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet Regimens (06/14/13) Genotypic Analyses of Pre-Existing HIV-1 Drug Resistance in Proviral HIV-1 DNA from PBMCs in Suppressed Patients Switching to RPV/FTC/TDF (06/14/13) Primary and Secondary Analyses of Emergent Drug Resistance through Week 96 from the Phase 3 Studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (06/14/13) Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B (06/12/13) Subtyping Analysis of Hepatitis C Virus Using the INNO-LiPA assay and NS5B Sequencing (06/12/13) Advanced Mechanistic Studies of GSK1265744, a New HIV Integrase Inhibitor (INI) Dosed by Oral Administration or Long-Acting Parenteral Injection (06/11/13) Integrase Genotypic and Phenotypic Predictors of Antiviral Response to Dolutegravir (DTG) in Subjects With Resistance to Integrase Inhibitors (INIs) (06/11/13) Evolution of Integrase in Virus at Protocol-Defined Virologic Failure From the VIKING-3 Study (06/11/13) In Vitro Efficacy and Resistance Profiling of Protease Inhibitors Against a Novel HCV Genotype 3a Replicon (06/09/13) Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV is Driven by Higher TFV-DP Loading in Target cells (06/09/13) Evolution of the HCV Viral Population from the One Patient with S282T Detected at Relapse after Sofosbuvir Monotherapy (06/09/13) Analysis and Characterization of treatment-Emergent Resistance in ART-Experienced, Integrase Inhibitor-Naïve Subjects With Dolutegravir (DTG) vs Raltegravir (RAL) in SAILING (ING111762) (06/09/13) Epidemiology of Dolutegravir (DTG) Resistance in ~700 RAL-Resistant Isolates (06/09/13)